Listen to the audio version of this article (generated by AI).
Listen to the audio version of this article (generated by AI).
Revenue rose 7% to HUF 680.2 bln and operating profit climbed 8% to HUF 204.5 bln.
A net financial loss of HUF 9.5 bln, after a net gain of HUF 5.8 bln in the base period, weighed on the bottom line.
FX losses came to HUF 24.7 bln in Q1-Q3, including HUF 18.9 bln in Q3 alone, mostly due to the weaker dollar and the stronger forint, Richter said.
Richter also noted the negative impact of a “slightly higher” effective tax rate, boosted by deferred tax expenses. Earnings per share came to HUF 893.
North America was Richter’s biggest market in Q1-Q3, generating turnover of HUF 200.8 bln, up 9%. Royalties from sales of Vraylar, the brand name there for Richter’s antipsychotic cariprazine, came to HUF 181 bln, an increase of 10%.
Richter adjusted its full-year guidance for pharmaceutical revenue, at constant exchange rates, to “close to EUR 2.3 bln”.
Operating profit, adjusted for one-offs and at constant exchange rates, is expected to grow 8-10%.
Pharma sales reached EUR 1.67 bln in Q1-Q3, while the segment’s clean operating profit rose nearly 8% to EUR 534 mln.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
